Iberdomide
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Iberdomide
- Molecular weight
- 449.51
- Structure (SMILES)
- O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1
- cc 220
- CC-220
- iberdomida
- Iberdomida
- IBERDOMIDA
- iberdomide
- Iberdomide
- IBERDOMIDE
- IBERDOMIDE (CC220)
- iberdomide [INN]
- IBERDOMIDE [USAN]
- Iberdomide [WHO-DD]
- iberdomide cc220
- iberdomide inn
- iberdomide usan
- iberdomide who dd
- CAS registry numbers
- 1323403-33-3
- ChEMBL ID
- CHEMBL3989927
- InChIKey
- IXZOHGPZAQLIBH-NRFANRHFSA-N
- PubChem compound IDs
- 67335295
- RxNorm IDs (RxCUI)
- 2749731
- FDA ingredient codes (UNII)
- 8V66F27X44
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- iberdomide
- Type
- Synthetic organic
- Drug name stem
- -domide
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Binding
- Action type
- Binding
- Target
- cereblon
- Gene symbol
- CRBN
- Protein identifier
- Q96SW2
- Median affinity
- 7.22
- Affinity units
- pIC50
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase modulator
- Action type
- MODULATOR
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Protein identifier
- P62877
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase modulator
- Action type
- MODULATOR
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Protein identifier
- Q13619
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase modulator
- Action type
- MODULATOR
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Protein identifier
- Q16531
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase modulator
- Action type
- MODULATOR
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Protein identifier
- Q96SW2
Open Targets mechanisms
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase modulator
- Action type
- MODULATOR
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Condition
- Multiple Myeloma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Renal Insufficiency
- Highest recorded phase
- 1
- Condition identifier
- HP:0000083
- Subject identifier
- D051437
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 3
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005072
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005235
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006611
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018908
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0019338
- Highest recorded phase
- 2
- NCT04392037
- NCT04564703
- NCT04975997
- NCT04998786
- NCT05177536
- NCT05199311
- NCT05272826
- NCT05289492
- NCT05354557
- NCT05392946
- NCT05434689
- NCT05527340
- NCT05558319
- NCT05560399
- NCT05583617
- NCT05827016
- NCT05896228
- NCT06107738
- NCT06121843
- NCT06179888
- NCT06215118
- NCT06216158
- NCT06232044
- NCT06348108
- NCT06465316
And 1 more, listed on the interactive page.
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 88.18
- Calculated partition coefficient (ALogP)
- 1.86
- Calculated partition coefficient (XLogP)
- 1.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 33
- Molecular formula
- C25H27N3O5
- Monoisotopic mass
- 449.19507097
- Natural product
- Yes
- Recorded assays
- 235
- Active assays
- 31
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (53)
- 2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects
- 3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
- A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Phase 2 Study With CC-220 in Skin Sarcoidosis
- A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects
- A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants
- A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
- A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
- A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
- Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
- COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
In development for (8)
- Kidney failure Phase 1
- Neuroblastoma Phase 1
- Non-Hodgkin lymphoma Phase 1
- Plasma cell myeloma Phase 3
- Sarcoidosis Phase 2
- Skin sarcoidosis Phase 2
- Smoldering plasma cell myeloma Phase 2
- Systemic lupus erythematosus Phase 2